These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38471620)

  • 1. CAR T treatment beyond cancer: Hope for immunomodulatory therapy of non-cancerous diseases.
    Yang Z; Liu Y; Zhao H
    Life Sci; 2024 May; 344():122556. PubMed ID: 38471620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T therapy beyond cancer: the evolution of a living drug.
    Baker DJ; Arany Z; Baur JA; Epstein JA; June CH
    Nature; 2023 Jul; 619(7971):707-715. PubMed ID: 37495877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.
    Lundh S; Jung IY; Dimitri A; Vora A; Melenhorst JJ; Jadlowsky JK; Fraietta JA
    Clin Exp Med; 2020 Nov; 20(4):469-480. PubMed ID: 32333215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry.
    Maryamchik E; Gallagher KME; Preffer FI; Kadauke S; Maus MV
    Cytometry B Clin Cytom; 2020 Jul; 98(4):299-327. PubMed ID: 32352629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor-based therapies beyond cancer.
    Velasco-de Andrés M; Muñoz-Sánchez G; Carrillo-Serradell L; Gutiérrez-Hernández MDM; Català C; Isamat M; Lozano F
    Eur J Immunol; 2023 Mar; 53(3):e2250184. PubMed ID: 36649259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.
    Roselli E; Faramand R; Davila ML
    J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33463538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering enhanced CAR T-cells for improved cancer therapy.
    Milone MC; Xu J; Chen SJ; Collins MA; Zhou J; Powell DJ; Melenhorst JJ
    Nat Cancer; 2021 Aug; 2(8):780-793. PubMed ID: 34485921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-T cell therapy: current limitations and potential strategies.
    Sterner RC; Sterner RM
    Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy.
    Dabas P; Danda A
    Med Oncol; 2023 Aug; 40(9):275. PubMed ID: 37608202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.
    Marofi F; Saleh MM; Rahman HS; Suksatan W; Al-Gazally ME; Abdelbasset WK; Thangavelu L; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Pathak Y; Naimi A; Baradaran B; Nikoo M; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):374. PubMed ID: 34215336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
    Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
    Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].
    Hiramatsu H
    Rinsho Ketsueki; 2018; 59(10):1948-1954. PubMed ID: 30305496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
    Yoo HJ; Harapan BN
    Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
    Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
    Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor T-cells (CARs) in Cancer Treatment.
    Zam W; Assaad A
    Curr Mol Pharmacol; 2022; 15(3):532-546. PubMed ID: 34382510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.